海正生材：持股5%以上股东减持1%股份，减持计划实施完毕

Core Viewpoint - Sinopec Capital, a shareholder holding more than 5% of the shares, has reduced its stake in Haizheng Biomaterials due to funding needs for business development, completing the reduction plan as of November 11 [1] Group 1: Shareholder Reduction - Sinopec Capital originally held 12,814,894 shares, accounting for 6.32% of the total share capital [1] - The reduction plan was disclosed on September 26, 2025, allowing for a maximum reduction of 2,026,700 shares, which is up to 1% of the total share capital [1] - As of November 11, Sinopec Capital has completed the reduction, selling 2,026,700 shares for a total amount of 26.73 million yuan, reducing its holding to 10,788,194 shares, which is 5.32% of the total share capital [1]